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Infection of cells with DNA viruses triggers innate immune re-
sponses mediated by DNA sensors. cGMP-AMP synthase (cGAS)
is a key DNA sensor that produces the cyclic dinucleotide cGMP-
AMP (cGAMP) upon activation, which binds to and activates stim-
ulator of interferon genes (STING), leading to IFN production and
an antiviral response. Kaposi’s sarcoma-associated herpesvirus
(KSHV) is a DNA virus that is linked to several human malignancies.
We report that KSHV infection activates the cGAS-STING pathway,
and that cGAS and STING also play an important role in regulating
KSHV reactivation from latency. We screened KSHV proteins for
their ability to inhibit this pathway and identified six viral proteins
that block IFN-β activation through this pathway. This study is the
first report identifying multiple viral proteins encoded by a human
DNA virus that inhibit the cGAS-STING DNA sensing pathway. One
such protein, viral interferon regulatory factor 1 (vIRF1), targets
STING by preventing it from interacting with TANK binding kinase 1
(TBK1), thereby inhibiting STING’s phosphorylation and concomi-
tant activation, resulting in an inhibition of the DNA sensing path-
way. Our data provide a unique mechanism for the negative
regulation of STING-mediated DNA sensing. Moreover, the deple-
tion of vIRF1 in the context of KSHV infection prevented efficient
viral reactivation and replication, and increased the host IFN re-
sponse to KSHV. The vIRF1-expressing cells also inhibited IFN-β
production following infection with DNA pathogens. Collectively,
our results demonstrate that gammaherpesviruses encode inhibi-
tors that block cGAS-STING–mediated antiviral immunity, and that
modulation of this pathway is important for viral transmission and
the lifelong persistence of herpesviruses in the human population.
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Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV8) isthe etiological agent of several human malignancies, in-
cluding Kaposi’s sarcoma (KS), multicentric Castleman’s disease,
and primary effusion lymphoma (1, 2). Evasion of the host innate
immune response is essential for viral infection, replication, la-
tency, transmission, and lifelong persistence.
A member of the gammaherpesvirus subfamily, KSHV con-
tains a large dsDNA genome that encodes for more than 80
ORFs. Different pattern recognition receptors (PRRs), such as
Toll-like receptors (TLRs), nucleotide-binding domain leucine-rich
repeat-containing (NLR) proteins, and retinoic acid-inducible
gene-I–like receptors (RLRs), are activated upon KSHV infection
in different cell types (3–5). As is the case with many pathogens,
multiple PRRs can detect an incoming pathogen in the cell.
Depending on the cell type, detection of viral DNA may take place
in the nucleus (6) or in the cytoplasm due to premature release of
the herpesviral DNA into the cytoplasm (7). It is plausible that
defective herpesvirus virions release their genomic contents into
the cytoplasm rather than the nucleus and that this viral DNA
triggers cytosolic DNA sensors to be activated. Additionally, HSV-1
infection induces mitochondrial stress, which results in the re-
lease of mtDNA into the cytoplasm, thereby activating the cGMP-
AMP synthase (cGAS) and stimulator of interferon-dependent
genes (STING) DNA sensing pathway (8).
cGAS and STING are important mediators of the innate im-
mune response to DNA viruses. Activation of this pathway leads
to the production of type I interferon (IFN) and a subsequent
antiviral response. STING was identified as a critical regulator of
the DNA sensing pathway (9, 10) that activates type I IFN signaling
by binding foreign DNA directly (11) or through the action of
sensors, such as cGAS (12–15). Upon detecting DNA from DNA
viruses, including HSV-1 (12, 13), cGAS synthesizes cGMP-AMP
(cGAMP), a moiety that binds to and activates STING to induce
IFN (12, 13). As is the case with other pathogens, including HSV-1,
it is highly plausible that multiple DNA sensing pathways can detect
KSHV. It is currently not known whether the DNA sensing pathway
mediated through cGAS and STING is also activated upon KSHV
infection and whether viral proteins expressed by KSHV inhibit
this pathway.
Results
Knockdown of cGAS and STING Reduces IFN-β Activation in Endothelial
Cells During Primary Infection with KSHV. To determine whether
KSHV is sensed by the cGAS-STING pathway, we first tested hu-
man umbilical vein endothelial cells (HUVECs) and EA.hy926
endothelial cells for their ability to respond to foreign DNA,
because endothelial cells are physiologically relevant for KSHV
infection and KS. Both HUVECs (Fig. 1A) and EA.hy926
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endothelial cells (Fig. 1B) displayed activation of the DNA path-
way, as measured by increased IFN-β transcription when treated
with exogenous DNAs, including an IFN stimulatory DNA
fragment from Listeria monocytogenes (ISD90), the HSV-1 ge-
nome (HSV60), and Escherichia coli DNA. Both HUVECs (Fig.
1C) and EA.hy926 cells (Fig. 1D) secreted IFN-β protein upon
treatment with these DNAs. cGAMP itself could trigger an IFN-β
response in these cell lines (Fig. 1 A–D). Moreover, both HUVECs
and EA.hy926 cells mounted an IFN-β response upon HSV-1 pri-
mary infection (Fig. 1 E and F, respectively), confirming that the
DNA sensing pathway is indeed active in these cells. Hence,
these two endothelial cell lines were used to investigate whether
the cGAS-STING pathway responded to KSHV infection.
HUVECs were transfected with cGAS or STING siRNAs or a
nonspecific (NS) control siRNA, and 72 h later, they were infected
with KSHV. Cells were harvested at 8 h postinfection, and IFN-β
mRNA levels were examined. Knockdown of either STING (Fig.
1G) or cGAS (Fig. 1H) decreased the induction of IFN-β mRNA
from KSHV-infected HUVECs, as well as IFN-β protein as
measured by ELISA (Fig. S1A). A similar decrease in IFN-β
mRNA levels was observed in KSHV-infected EA.hy926 en-
dothelial cells transfected with siRNAs against STING (Fig. 1I)
or cGAS (Fig. 1J), or stably depleted for either STING (Fig.
S1B) or cGAS (Fig. S1C). Knockdown of STING and cGAS in
HUVECs and EA.hy926 cells was also confirmed by immuno-
blots, as shown in Fig. 1 K and L. Interestingly, KSHV infection
induced only a modest IFN-β response upon primary infection
of these endothelial cells, suggesting that gammaherpesviruses
may encode multiple proteins that inhibit this cGAS-STING
pathway (16).
To facilitate our studies, we selected an internal repeat
region within the KSHV genome to simulate activation of the
Fig. 1. KSHV primary infection can activate a STING-cGAS–dependent IFN-β response. IFN-β mRNA in HUVECs (A) or EA.hy926 endothelial cells (B) was
measured by real-time qPCR 4 h after transfection of various DNA fragments (ISD90, HSV60, and E. coli DNA at 5 μg/mL) and cGAMP (5 μg/mL) with Lip-
ofectamine 2000 (Life Technologies). The relative amount of IFN-β mRNA was normalized to the 18S ribosomal RNA level in each sample, and the fold
difference between the treated and mock samples was calculated. IFN-β in HUVECs (C) or EA.hy926 endothelial cells (D) was measured by ELISA 24 h after the
same treatment described in A and B. (E) HUVECs or EA.hy926 cells were infected by HSV-1 at an MOI of 10, and IFN-β mRNA levels were measured 4 h
postinfection (hpi) by real-time qPCR. The relative amount of IFN-β mRNA was normalized to the 18S ribosomal RNA level in each sample, and the fold
difference between the uninfected and HSV-1–infected samples was calculated. (F) HUVECs or EA.hy926 cells were infected with HSV-1 at an MOI of 10, and
IFN-β protein levels were measured 24 hpi by ELISA. HUVECs were treated with NS, STING (G), or cGAS (H) siRNA for 72 h. The treated cells were then infected
with KSHV (30 genome copies per cell) for 8 h before IFN-βmRNA was measured by real-time qPCR. The relative amount of IFN-βmRNA was normalized to the
18S ribosomal RNA level in each sample, and the fold difference between the siSTING or sicGAS sample compared with the siNS sample was calculated.
Knockdown efficiency of STING and cGAS was monitored by real-time qPCR, and their mRNA levels were normalized to the actin mRNA level in each sample.
EA.hy926 cells were treated with NS, STING (I), or cGAS (J) siRNA for 72 h. The treated cells were then infected with KSHV (30 genome copies per cell) for 8 h
before IFN-β mRNA levels were measured by real-time qPCR. The relative amount of IFN-β mRNA was normalized to the 18S ribosomal RNA level in each
sample, and the fold difference between the siSTING or sicGAS sample compared with the siNS sample was calculated. Knockdown efficiency of STING or cGAS
was monitored by real-time qPCR, and their mRNA levels were normalized to the actin mRNA level in each sample. HUVECs (K) and EA.hy926 cells (L) were
treated with NS, STING, or cGAS siRNA for 72 h. Cell lysates were harvested, and endogenous STING and cGAS were detected by Western blot analysis. Data
are presented as mean ± SD from at least three independent experiments. *P < 0.05; **P < 0.01 (both by Student’s t test).















cGAS-STING pathway during KSHV infection. This genomic
fragment is composed of repeat sequences, direct repeat 1 (DR1)
and direct repeat 2 (DR2), which were previously reported to
induce an IFN response (17). We used a 120-bp dsDNA frag-
ment (named KSHV120) containing the juxtaposed DR1 and
DR2 regions (Fig. S2A) in the KSHV genome (accession no.
GQ994935.1). When transfected into HUVECs or EA.hy926
cells, KSHV120 was able to induce IFN-β transcription (Fig. 2 A
and B). Similar to previous studies with other DNA sensors for
HSV-1 and vaccinia virus genomes in which HSV60 or 70mer
from vaccinia virus (VACV70) sequences was used, respectively,
we did not observe sequence specificity in the ability of
KSHV120 to activate the cGAS-STING pathway. The individual
DR1 or DR2 (69mer) sequences also increased IFN-β mRNA
levels (Fig. 2 A and B).
We next determined whether STING and cGAS were re-
quired for the increase in IFN-β induction mediated by this
KSHV120 fragment mimic. Cell lysates were subjected to im-
munoblotting for interferon regulatory factor 3 (IRF3) and
TANK binding kinase 1 (TBK1). We found that both IRF3 and
TBK1 were phosphorylated and activated in response to trans-
fection of KSHV120 into HUVECs, and that levels of phos-
phorylated IRF3 and TBK1 were decreased upon STING or
cGAS knockdown, although the total levels of IRF3 and TBK1
remained unchanged (Fig. 2C). Similarly, phosphorylation of
IRF3 and TBK1 was inhibited in KSHV120-transfected EA.
hy926 cells with STING or cGAS knockdown (Fig. 2D). Con-
sistently, knockdown of STING (Fig. 2E) or cGAS (Fig. 2F) in
HUVECs reduced the induction of IFN-β mRNA levels after
transfection of the KSHV120 DNA fragment. Furthermore, IFN-β
protein levels were increased upon transfection of KSHV120 into
EA.hy926 endothelial cells (Fig. S2B), and IFN-β transcript levels
were reduced when STING or cGAS was depleted from these
cells (Figs. 2 G and H). Further experiments demonstrated that
KSHV120 was capable of binding to ectopically expressed
STING and cGAS in HEK293T cells (Fig. S2C).
Knockdown of cGAS and STING Increases KSHV Viral Reactivation
from Latency. We next determined the effect of STING and
cGAS on KSHV reactivation from latency, because reactivation
is essential for KSHV persistence and is also likely to trigger an
innate immune response. We used rKSHV.219 iSLK (iSLK.219)
cells (18), which contain a latent version of the KSHV genome
expressing a constitutive GFP marker and a doxycycline (Dox)-
inducible version of the essential lytic transactivator protein,
RTA, to enable entry into the lytic cycle. The viral genome also
contains an RFP marker driven by a lytic cycle-specific promoter,
which can be used to monitor lytically reactivated cells (19). The
iSLK.219 cells were transfected with NS, STING, or cGAS
siRNAs and reactivated from latency by Dox treatment. As
shown in Fig. 3A, cells treated with Dox for 48 h and 72 h showed
greater reactivation as measured by RFP expression when
siRNAs against STING or cGAS were transfected into these cells
compared with NS siRNA. There was a five- to eightfold in-
crease when STING or cGAS was depleted from these cells (Fig.
S3A). Upon reactivation, there was an increase in IFN-β mRNA
levels in the NS siRNA-treated group (Fig. 3 B and C), indicating
that reactivation of KSHV triggered an IFN-β response. By con-
trast, IFN-β induction was significantly suppressed in STING-
depleted (Fig. 3B) or cGAS-depleted (Fig. 3C) cells. A similar
trend was seen for IFN-β protein levels, as measured by ELISA
(Fig. 3D). Fig. 3E demonstrates that both IRF3 and TBK1 were
phosphorylated and activated in response to KSHV reactivation,
and that the levels of phosphorylated IRF3 and TBK1 were de-
creased upon STING or cGAS knockdown in these cells, whereas
the total levels of IRF3 and TBK1 were unchanged. To measure
viral reactivation, several KSHV lytic genes were analyzed
in reactivated cells that were transfected with NS, STING, or
cGAS siRNA. As shown in Fig. 3F, there was increased lytic
gene transcription following reactivation in STING- and cGAS-
depleted iSLK.219 cells compared with the NS control. To de-
termine whether viral reactivation resulted in a majority of KSHV
genes being expressed, indicative of complete reactivation, we
Fig. 2. KSHV DNA motif induces a STING-cGAS–dependent IFN-β response. HUVECs (A) or EA.hy926 cells (B) were transfected with DR1, DR2, or KSHV120
fragments by Lipofectamine 2000 for 4 h before IFN-β mRNA levels were measured by real-time qPCR. The relative amount of IFN-β mRNA was normalized to
the 18S ribosomal RNA level in each sample, and the fold difference of the transfected samples compared with the mock sample was calculated. HUVECs (C)
or EA.hy926 cells (D) treated with NS, STING, or cGAS siRNA were transfected with KSHV120 for 4 h before cells were lysed for immunoblot analysis. HUVECs
were treated with NS, STING (E), or cGAS (F) siRNA for 72 h and then transfected with KSHV120 for 4 h before IFN-β mRNA levels were measured by real-time
qPCR. The relative amount of IFN-β mRNA was normalized to the 18S ribosomal RNA level in each sample, and the fold difference between the siSTING or
sicGAS sample compared with the siNS sample was calculated. STING or cGAS knockdown efficiency was monitored by real-time qPCR, and their mRNA levels
were normalized to the actin mRNA level in each sample. EA.hy926 cells were treated with NS, STING (G), or cGAS (H) siRNA for 72 h and then transfected with
KSHV120 for 4 h before IFN-β mRNA levels were measured by real-time qPCR. The relative amount of IFN-β mRNA was normalized to the 18S ribosomal RNA
level in each sample, and the fold difference between the siSTING or sicGAS sample compared with the siNS sample was calculated. STING or cGAS knockdown
efficiency was monitored by real-time qPCR, and their mRNA levels were normalized to the actin mRNA level in each sample. Data are presented as mean ± SD
from at least three independent experiments. *P < 0.05; ** P < 0.01 (both by Student’s t test).
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performed whole-viral genome transcriptional profiling. Knock-
down of cGAS and STING led to increased transcription of vir-
tually all KSHV viral genes upon reactivation compared with cells
transfected with the NS siRNA control (Fig. 3G and Fig. S3B).
Fig. 3. KSHV reactivation activates a cGAS-STING–dependent IFN-β response. (A) iSLK.219 cells were transfected with NS, STING, or cGAS siRNA for 72 h and
then treated with Dox for various time periods. GFP and RFP were monitored at 48 h and 72 h post-Dox treatment. (B and C) IFN-β mRNA levels 72 h post-Dox
treatment from A were measured by real-time qPCR. The relative amount of IFN-β mRNA was normalized to the 18S ribosomal RNA level in each sample, and
the fold difference between the siSTING or sicGAS sample compared with the siNS sample was calculated. Knockdown efficiency of STING (B) or cGAS (C) was
monitored by real-time qPCR, and their mRNA levels were normalized to the actin mRNA level in each sample. (D) IFN-β ELISA was performed 72 h post-
reactivation with Dox. (E) Immunoblot analysis of cell lysate 48 h post-Dox treatment of A. (F) RNA was extracted from iSLK.219 cells 72 h post-Dox treatment
of A, transcription of KSHV viral genes was monitored using real-time qPCR, and their mRNA levels were normalized to the actin mRNA level in each sample.
(G) iSLK.219 cells were treated as described in the main text. At 72 h post-Dox treatment, RNA was extracted from duplicate samples and KSHV viral transcript
levels were analyzed using a KSHV real-time qPCR-based whole-genome array. mRNA levels of viral genes were normalized to the mRNA levels of multiple
cellular housekeeping genes to yield delta cycle threshold (dCT) as a measure or relative expression. These values were then subjected to unsupervised clustering.
A heat map and dendrogram depicted by the brackets is shown. As shown in the key, higher transcript levels are indicated by red and lower levels are indicated by
blue. Data are presented as mean ± SD from at least three independent experiments. *P < 0.05; **P < 0.01 (both by Student’s t test). (Also Fig. S3B.)















cGAS-STING Screen Reveals Multiple Viral Proteins That Block IFN-β
Activation by the cGAS-STING Pathway. We next evaluated if indi-
vidual viral genes/proteins could modulate the cGAS-STING
pathway. We screened for viral proteins that inhibited IFN-β
promoter activation by first developing a screening assay based
on exogenous expression of cGAS and STING in HEK293T cells
(13). cGAS alone failed to activate the IFN-β promoter lucifer-
ase reporter in HEK293T cells, due to lack of STING expression
(Fig. 4A), as previously reported (13). Next, we ectopically
expressed a minimal amount of STING in HEK293T cells
without significantly inducing IFN-β (Fig. 4A). Under these
conditions, either STING alone or cGAS alone failed to induce
IFN-β promoter-driven luciferase activity, compared with the
vector control. However, when the same amounts of STING and
cGAS expression plasmids were cotransfected together with an
IFN-β promoter luciferase reporter construct, the IFN-β pro-
moter was highly activated. Using this assay, we performed a
screen (Fig. 4B) to identify which KSHV genes could inhibit
IFN-β activation due to activation of the STING-cGAS DNA
sensing pathway. Table S1 lists the average percentage of in-
hibition or induction of the cGAS-STING–mediated activation
of the IFN-β promoter, and Fig. 4C shows a waterfall plot of the
inhibitors on one end and activators on the other end. Fig. 4D
summarizes the data in a heat map indicating the modulation of
the cGAS-STING pathway by the KSHV ORFs. We found six
KSHV ORFs (ORF36, ORF 73, ORF57, vIRF1, ORF45, and
Fig. 4. Screening of KSHV ORFs that modulate the cGAS-STING–dependent pathway. (A) HEK293T cells were cotransfected with 50 ng of IFN-β promoter
luciferase and various plasmids (pCDNA3, 2.5 ng of pCDNA-STING-HA, or 50 ng of pUNO-cGAS or pCDNA-STING-HA and pUNO-cGAS combined). Luciferase
activity was measured 36 h posttransfection in the cell lysates. A CMV-driven Renilla plasmid was cotransfected as a transfection control. (B) Schematic of
cGAS-STING–based screening. Cells were transfected with the same amount of STING and cGAS expression plasmid, plus 100 ng of KSHV ORF expression
plasmid or EV. (C) Waterfall plot of the effect of KSHV ORFs on cGAS-STING– based screening. The top six inhibitors and one activator are shown. (D) Heat
map of the effect of KSHV ORFs on the cGAS-STING pathway. Higher IFN-β promoter luciferase activation levels are indicated by red, whereas lower levels are
indicated by blue, which corresponds to a higher degree of inhibition. The six inhibitors are marked with a bracket. (E) Top six KSHV ORF inhibitor expression
plasmids were cotransfected with STING and cGAS expression plasmids. Thirty-six hours later, IFN-β mRNA levels were measured by real-time qPCR. The
relative amount of IFN-β mRNA was normalized to the 18S ribosomal RNA level in each sample, and the fold changes in IFN-β mRNA levels compared with the
vector control are displayed on the y axis. (F) Top six KSHV ORF inhibitor expression plasmids were cotransfected with STING and cGAS expression plasmids,
and IFN-β protein levels were measured by ELISA 36 h posttransfection. (G) K13 expression plasmid was cotransfected with STING and cGAS expression
plasmids, and IFN-β mRNA levels were measured by real-time qPCR 36 h posttransfection. The relative amount of IFN-β mRNA was normalized to the 18S
ribosomal RNA level in each sample, and the fold change between the K13-expressing vs. vector-expressing cells was calculated. (H) K13 was cotransfected
with STING and cGAS plasmids, and IFN-β protein levels were measured by ELISA 36 h posttransfection. (I) Varying doses of the top six KSHV ORF inhibitor
expression plasmids (25 ng, 50 ng, or 100 ng) were cotransfected with STING and cGAS expression plasmids, and IFN-β promoter luciferase activity was
measured 36 h posttransfection. (J) Varying doses of a K13 expression plasmid (25 ng, 50 ng, or 100 ng) were cotransfected with STING and cGAS expression
plasmids, and IFN-β promoter-driven luciferase activity was measured 36 h posttransfection. Data are presented as mean ± SD from at least three independent
experiments. *P < 0.05; **P < 0.01 (both by Student’s t test).
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Fig. 5. KSHV vIRF1 inhibits cGAS-STING sensing and promotes HSV-1 replication. HUVECs or EA.hy926 endothelial cells were transduced with EV or vIRF1-
expressing lentivirus to generate EV or vIRF1-expressing cells. These cells were used in the following experiments unless otherwise noted. (A) IFN-β mRNA
levels in transduced HUVECs were measured by real-time qPCR 4 h posttransfection of various DNA fragments (ISD90, HSV60, VACV70, KSHV120, and E. coli
DNA at 5 μg/mL). The relative amount of IFN-β mRNA was normalized to the 18S ribosomal RNA level in each sample, and the fold differences between the
treated samples compared with the mock samples were calculated. (B) IFN-β protein levels in HUVEC transduced cells were measured by ELISA 24 h post-
transfection of various DNA fragments (ISD90, HSV60, VACV70, KSHV120, and E. coli DNA at 5 μg/mL). (C) Transduced EA.hy926 cells were treated, and IFN-β
mRNA levels were measured as in A. (D) Transduced EA.hy926 cells were treated, and IFN-β protein levels were measured as in B. (E) Transduced HUVECs were
infected by HSV-1 at an MOI of 10. IFN-β mRNA levels in these cells were measured by real-time qPCR 4 hpi. The relative amount of IFN-β mRNA was
normalized to the 18S ribosomal RNA level in each sample, and the fold difference between the HSV-1–infected samples compared with the uninfected
mock samples was calculated. (F) Transduced HUVECs were infected by HSV-1 at an MOI of 10. IFN-β protein levels were also measured by ELISA 24 hpi.
(G) Transduced EA.hy926 cells were treated and IFN-β mRNA was measured as in E. (H) Transduced EA.hy926 cells were treated and IFN-β protein levels
were measured as in F. Transduced HUVECs (I) or EA.hy926 cells (J) were infected with HSV-1 at various MOIs (0.01, 0.1, or 1). At 24 or 48 hpi, supernatants
were subjected to a plaque assay to obtain the HSV-1 viral titer. (K) Cells from Jwere monitored by bright-field microscopy 24 hpi. (L) vIRF1 protein levels were
monitored by immunoblotting in HUVECs or EA.hy926 cells transduced with EV or vIRF1-expressing lentivirus. Data are presented as mean ± SD from at least
three independent experiments. * P < 0.05; **P < 0.01 (both by Student’s t test).















ORF55) that could inhibit the cGAS-STING pathway between
threefold and sixfold in our screen, and we validated these
candidates by measuring IFN-β mRNA levels by real-time
quantitative PCR (qPCR) (Fig. 4E), as well as measuring IFN-β
protein levels by ELISA in HEK293T cells (Fig. 4F). Only one
KSHV ORF, KSHV K13/vFLIP, activated the IFN-β promoter
through the STING-cGAS–mediated pathway greater than
threefold (Fig. 4G). IFN-β protein levels were also increased by
KSHV K13/vFLIP, as measured by ELISA (Fig. 4H). Next, a
dose–response assessment of the viral modulators was per-
formed. Each viral inhibitor showed a dose-dependent inhibition
of this pathway (Fig. 4I), whereas the activator, KSHV K13/
vFLIP, showed a dose-dependent increase of this pathway (Fig.
4J). KSHV K13/vFLIP’s effects on the IFN-β promoter are likely
to be mediated by NF-κB because vFLIP activates NF-κB (20).
To evaluate the specific involvement of KSHV ORFs in the
STING-cGAS pathway, we also tested whether the individual
KSHV ORFs were directly modulating the IFN-β promoter in
the absence of exogenous cGAS and STING expression. Ex-
pression plasmids for the KSHV ORFs and the IFN-β promoter
luciferase were cotransfected in HEK293T cells. These data are
shown in Table S2. We found that the majority of viral genes/
proteins did not affect IFN-β promoter activity in the absence of
exogenous STING and cGAS.
KSHV vIRF1 Inhibits STING Function by Disrupting the TBK1–STING
Interaction. The six inhibitors that suppressed IFN-β activation
mediated by cGAS-STING may be able to inhibit this pathway at
multiple nodes downstream of cGAS and/or STING. In this
study, we focused only on one of the viral inhibitors, KSHV
vIRF1/K9 (21), because vIRF1 is only encoded by KSHV, it does
not have a homolog in other human herpesviruses, and we
wanted to better clarify the KSHV-specific mechanism of blocking
cGAS-STING–mediated innate immune responses.
We transduced either EA.hy926 cells or HUVECs with a
vIRF1-expressing lentivirus or control [empty vector (EV)] len-
tivirus to generate EV- or vIRF1-expressing cell lines. These EV
and vIRF1 cell lines were then transfected with different DNA
fragments, including ISD90, HSV60, VACV70, KSHV120, and
E. coli DNA. The mRNA and protein level of IFN-β from cells
transfected with these fragments was measured by real-time
qPCR and ELISA. IFN-β transcription and protein levels were
greatly increased in the EV cells in response to the DNA stimuli
but were significantly reduced in the vIRF1-expressing HUVECs
(Fig. 5 A and B), suggesting that vIRF1 was inhibiting the DNA-
induced IFN pathway. Similar experiments were performed in
EA.hy926 cells, and, again, vIRF1 was able to block the DNA-
triggered IFN-β response (Fig. 5 C andD). We then tested whether
IFN-β induction triggered by DNA virus infection was blocked
in vIRF1-expressing EA.hy926 cells. We infected the EV- and
vIRF1-expressing HUVECs with HSV-1 virus at a multiplicity of
infection (MOI) of 10 and found that vIRF1 expression led to a
reduced IFN-β response against HSV-1, compared with the
control, at both the transcriptional (Fig. 5E) and protein (Fig.
5F) levels. Similar results were observed in EV- vs. vIRF1-
expressing EA.hy926 cells infected with HSV-1 (Fig. 5 G and H).
Concordantly, different amounts of HSV-1 (MOIs of 0.01, 0.1,
and 1) showed greater replication in the vIRF1-expressing EA.
hy926 cells or HUVECs compared with the vector control cells
(Fig. 5 I–K). In close correlation with this result, the HSV-1 titer
in the supernatants from infected vIRF1-expressing cells was
much higher than the titer from the EV cells. These data provide
a biological measure of attenuated IFN-β induction in vIRF1-
expressing cells. vIRF1 expression was confirmed by immuno-
blotting (Fig. 5L).
Next, we tested whether ablation of vIRF1 in KSHV-infected
cells would affect KSHV replication, as well as the host immune
response to KSHV infection. We used siRNA against vIRF1
(sivIRF1) to deplete vIRF1 in reactivated iSLK.219-infected cells,
and we also used an NS control siRNA (siNS) (Fig. 6C). As shown
in Fig. 6 A and B, knockdown of vIRF1 resulted in a higher amount
of IFN-β gene expression and protein secretion in response to
KSHV reactivation. Consistent with this observation, knockdown of
vIRF1 also suppressed viral gene transcription and lytic viral repli-
cation, as indicated by quantitative real-time PCR (qPCR) (Fig. 6D)
and red fluorescence in the reactivated iSLK.219 cells (Fig. 6 E and
F). Furthermore, immunoblots of these samples confirmed endog-
enous vIRF1 knockdown at the protein level (Fig. 6G). Collectively,
these data provide a physiological role for vIRF1 in ablating the host
innate immune response during the KSHV life cycle.
Next, we probed the mechanism of action of vIRF1 on the
cGAS-STING pathway. cGAMP, the product of cGAS, activated
IFN-β transcription (Fig. 7A) and protein production (Fig. 7B) in
EV-expressing HUVECs, but this IFN activation was blocked in
HUVECs expressing vIRF1. Similar results were seen in EV-
and vIRF1-expressing EA.hy926 cells (Fig. 7 C and D). This
result was seen in both EA.hy926 cell lines and HUVEC lines,
suggesting that vIRF1 acted downstream of cGAS. It has been
previously reported that vIRF1 can block IFN-β signaling down-
stream of IRF3 phosphorylation (22, 23). We cotransfected
STING, cGAS, TBK1, IRF3sa (a constitutively activated form of
IRF3), or a combination of these plasmids including an IFN-β
promoter luciferase reporter plasmid, with either an EV- or
vIRF1-expression plasmid, into HEK293T cells (Fig. S4 A and B).
Thirty-six hours later, cells were harvested and luciferase activity
was measured. We found that vIRF1 inhibited TBK1- or IRF3sa-
triggered IFN-β luciferase activity in 293T cells, indicating that
vIRF1 was able to block the cGAS-STING pathway downstream
of the IRF3 phosphorylation step (Fig. S4 A and B). This result is
consistent with earlier reports (22, 23).
To determine if vIRF1 could also block a step before IRF3
phosphorylation, we stimulated the cGAS-STING pathway by
ISD treatment in EV- or vIRF1-expressing EA.hy926 cells and
HUVECs, and observed that phosphorylation of IRF3 and
TBK1 was also inhibited in the vIRF1-expressing cells compared
with EV-expressing cells, suggesting a novel mechanism of
vIRF1 inhibition of this pathway (Fig. 7 E and F). Interestingly, it
was previously reported that STING can be phosphorylated by
TBK1 after DNA stimulation and that this phosphorylation
correlated with activation and further signaling (9, 10, 15).
Consistent with previous reports, we also observed phosphory-
lated STING running at a higher molecular weight following 6 h
of ISD90 stimulation in both EA.hy926 and HUVEC control
cells. However, we did not observe higher molecular weight
bands for STING in cells stably expressing vIRF1, suggesting
that the cGAS-STING pathway was also blocked by vIRF1 at the
level of STING phosphorylation, in addition to the CBP/p300
level as previously reported (22, 23) (Fig. 7 E and F).
Importantly, when we ectopically coexpressed vIRF1 and
STING plasmids in HEK293T cells, we found that vIRF1 pulled
down STING and, reciprocally, STING coimmunoprecipitated
vIRF1 (Fig. 7 G and H). We also tested the interaction between
different domain mutants of vIRF1 (vIRF1-N, 1–223 aa; vIRF1-C,
200–449 aa) and STING (STING-N, 1–195 aa; STING-C, 181–
379 aa) (13). It appears that multiple domains of vIRF1
and STING interact with each other when overexpressed in
HEK293T cells (Fig. S4 C and D). We further confirmed the
interaction between endogenous STING and stably expressed
vIRF1 in EA.hy926-vIRF1–expressing cells, which is consistent
with our finding in HEK293T cells (Fig. 7I). It was reported
that TBK1 could directly associate with STING and phosphor-
ylate STING (24, 25). Therefore, we tested if KSHV vIRF1, as a
STING-associated protein, could disrupt the association of
TBK1 and STING. We cotransfected STING and TBK1 ex-
pression plasmids in HEK293T cells with or without different
amounts of vIRF1 expression plasmid (Fig. 7J). Consistent with
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previous reports, we were able to detect STING phosphorylation
when TBK1 was overexpressed, and STING was successfully
pulled down with TBK1. However, when vIRF1 was present,
STING could no longer interact with TBK1. We also performed
a semiendogenous coimmunoprecipitation assay for STING and
TBK1 to investigate whether vIRF1 could inhibit their in-
teraction. We made a stable V5 epitope-tagged STING HEK293
cell line and transfected pUNO-cGAS plasmid to activate the
DNA sensing pathway. Cells were harvested, lysed, and subjected
to coimmunoprecipitation with anti-V5 antibody. As shown in Fig.
7K, we were able to detect endogenous TBK1 being pulled down
with STING. Furthermore, the interaction was disrupted in the
presence of vIRF1, which is consistent with our earlier findings.
Moreover, immunofluorescence data showed vIRF1 was located in
both nuclear and cytosolic compartments, as previously reported
(26), and partially colocalized with STING in 293T-STING-V5
cells. However, vIRF1 does not appear to block STING trafficking
in HEK293T-STING-V5 cells when these cells were transfected
with a cGAS expression plasmid (Fig. S5). Overall, our data sug-
gest that by interacting with STING, vIRF1 is able to disrupt the
TBK1–STING interaction and prevent STING phosphorylation
and activation, which hinders innate immune activation in vIRF1-
expressing cells.
Discussion
Herpesviruses are readily transmitted in the human population
and must encode for a number of viral proteins that allow the
virus to evade innate immunity and establish lifelong persistence
in the host. Depending on the cell type, detection of viral DNA
may take place in the nucleus or in the cytoplasm due to pre-
mature release of the herpesviral DNA into the cytoplasm (7). It
is plausible that defective herpesvirus virions release their ge-
nomic contents into the cytoplasm rather than the nucleus,
triggering the activation of cytosolic DNA sensors. Additionally,
herpesvirus infection has been shown to induce mitochondrial
stress, which results in the release of mtDNA into the cytoplasm,
thereby activating the cGAS-STING DNA sensing pathway (8).
Either of these scenarios would result in activation of the cGAS-
STING DNA sensing pathway in KSHV-infected cells; hence, it
is plausible that viral proteins block this pathway.
We report that primary infection of endothelial cells with
KSHV, as well as reactivation of KSHV from latency, results in
the activation of type I IFN through a DNA sensing pathway
mediated by cGAS and STING. Although the cGAS-STING
pathway is activated upon KSHV infection, it is clear that the virus
is still able to establish latency in cells, suggesting that the virus
encodes proteins that down-regulate this pathway. To address
this question, we developed and established a cGAS-STING–
based assay for screening regulators of this pathway. Upon
screening more than 80 KSHV viral proteins, we successfully
identified a number of viral proteins that counteract the cGAS-
STING pathway and inhibit IFN-β induction by affecting any
step in this pathway. The steps downstream of TBK1 or IRF3
activation, for example, are shared by many other pathways,
such as the RLR and TLR pathways. Thus, we cannot rule out
the possibility that the candidates from this screening assay
affect other pathways in addition to the cGAS-STING pathway
we report here.
vIRF1 is present in both the cytoplasm and nucleus (26, 27)
(Fig. S5), and we have identified it as one of the top inhibitors in
our screen. vIRF1 broadly inhibited the cGAS-STING–mediated
induction of IFN-β in endothelial cells. In fact, vIRF1 has pre-
viously been shown to inhibit IFN-β activation through multiple
mechanisms, such as inhibiting p300 histone acetyltransferase or
blocking IRF-3 recruitment of the CBP/p300 coactivators (22,
23). We examined if vIRF1 could affect STING trafficking and
found that STING could still translocate to the perinuclear re-
gion even when vIRF1 was expressed, indicating that vIRF1 does
not seem to affect STING translocation. Furthermore, it has
been published that a point mutation at S366 of STING, which
affects STING phosphorylation and IFN-β activation, does not
seem to inhibit STING trafficking, suggesting that phosphory-
lation of STING occurs after trafficking (28). This report sup-
ports our findings that vIRF1 does not affect STING trafficking
but, rather, that it might inhibit STING at a step after trafficking.
Our data suggest that vIRF1 inhibits IFN-β signaling after IRF3 is
phosphorylated (Fig. S4 A and B), which is in agreement with
previous reports (23). However, we found that vIRF1 is also able to
affect IFN-β induction in response to DNA stimulation before IRF3
phosphorylation, suggesting the existence of a distinct mechanism of
vIRF1 from the previously reported recruitment of CBP/p300 (Fig.
7 E and F). Moreover, our data here show that vIRF1 can also
inhibit TBK1 binding to STING. Therefore, vIRF1 is a broad in-
hibitor of the IFN-β response and can block the cGAS-STING–
dependent DNA sensing pathway at multiple nodes in the pathway.
Fig. 6. Loss of KSHV vIRF1 results in elevated IFN-β production and atten-
uated KSHV reactivation and replication. The iSLK.219 cells were transfected
with either vIRF1 or NS siRNA for 24 h and then treated with Dox for 24 h.
(A) IFN-β mRNA levels were measured by qPCR. (B) IFN-β protein levels were
measured by ELISA. (C) vIRF1 mRNA levels were measured by qPCR. (D) Tran-
scription of KSHV viral genes was monitored using real-time qPCR. (E) GFP and
RFP were monitored at 48 h and 72 h post-Dox treatment. (F) Average RFP
intensities were calculated, and the reading of the siNS group at 48 h was set as
100%. Other groups were normalized to siNS group. (G) Immunoblot analysis of
vIRF1 using cell lysate 48 h and 72 h post-Dox treatment. Data are presented as
mean ± SD from at least three independent experiments. *P < 0.05; **P < 0.01
(both by Student’s t test).















Fig. 7. KSHV vIRF1 inhibits the cGAS-STING DNA sensing pathway. HUVECs or EA.hy926 endothelial cells were transduced with EV or vIRF1-expressing
lentivirus to generate EV- or vIRF1-expressing cells. These cells were used in the following experiments unless otherwise noted. (A) Transduced HUVECs
were transfected with cGAMP (5 μg/mL) with Lipofectamine 2000 for 4 h before cells were harvested, and IFN-β mRNA levels were measured by real-time
qPCR. The relative amount of IFN-β mRNA was normalized to the 18S ribosomal RNA level in each sample, and the fold difference between the cGAMP-
transfected samples compared with the mock samples was calculated. (B) Transduced HUVECs were transfected with cGAMP (5 μg/mL) with Lipofectamine
2000 for 24 h before supernatants were harvested, and IFN-β protein levels were measured by ELISA. (C) Transduced EA.hy926 cells were treated, and IFN-β
mRNA levels were measured as in A. (D) Transduced EA.hy926 cells were treated, and IFN-β protein levels were measured as in B. Transduced HUVECs (E )
or EA.hy926 cells (F ) were transfected with ISD90 for 0, 3, 6, and 9 h before harvest. Cells were lysed for immunoblot analysis. (G and H) Coimmuno-
precipitation of HA-STING and FLAG-vIRF1 in HEK293T cells. HA-STING and FLAG-vIRF1 expression plasmids were cotransfected into HEK293T cells, fol-
lowed by coimmunoprecipitation for STING using HA antibody or for vIRF1 using FLAG antibody. STING coimmunoprecipitates with vIRF1 (G), and vIRF1
coimmunoprecipitates with STING (H). (I) Coimmunoprecipitation of myc-vIRF1 and endogenous STING in EA.hy926-vIRF1 stable cells. Cell lysates were
precipitated with anti-myc antibody and subjected to immunoblotting. (J) Coimmunoprecipitation of HA-STING and FLAG-TBK1 in HEK293T cells
cotransfected with HA-STING and FLAG-TBK1 expression plasmids, with different doses of vIRF1 expression plasmid. Twenty-four hpi, protein lysates
were subjected to coimmunoprecipitation and the immunoprecipitates were immunoblotted for the presence of STING, vIRF1, and TBK1 as indicated.
(K ) Coimmunoprecipitation of STING-V5 and endogenous TBK1 in 293T-STING-V5 stable cells in the presence or absence of myc-vIRF1. Cell lysates were
precipitated with V5 antibody and subjected to immunoblotting. Data are presented as mean ± SD from at least three independent experiments. *P <
0.05; **P < 0.01 (both by Student’s t test).
E4314 | www.pnas.org/cgi/doi/10.1073/pnas.1503831112 Ma et al.
This strategy of targeting multiple steps in an innate immune
sensing pathway is a strategy shared by many viral proteins.
Importantly, we have shown that ablation of vIRF1 triggers a
stronger IFN-β response and results in attenuated viral reactivation
and replication. vIRF1 inhibited IFN-β production in response to
multiple established inducers of the cGAS-STING pathway, such
as specific DNA fragments, cGAMP, bacterial DNA, and DNA
virus infection. Notably, the ability of KSHV vIRF1 to attenuate
IFN responses to these DNA stimuli made vIRF1-expressing cells
more susceptible to other pathogens, such as HSV-1, suggesting
that KSHV could potentially modulate the host innate immune
response to secondary pathogen infection.
It was previously reported that upon DNA stimulation,
STING plays critical roles in recruiting both TBK1 and IRF3
(10, 15, 24). The formation of this complex facilitates TBK1
phosphorylation and activation, followed by STING and IRF3
phosphorylation by TBK1, thus leading to the activation of the
IFN-β response (24, 25, 28). In our study, vIRF1 interacted with
STING and significantly inhibited the binding of TBK1 to STING,
as well as the TBK1-mediated phosphorylation and activation of
STING, when cells were stimulated with ISD90 for up to 9 h. This
result is also consistent with our findings that both TBK1 and
IRF3 phosphorylation was greatly attenuated when vIRF1 was
present in the cells, and that this decrease in phosphorylation of
TBK1 and IRF3 is similar to the effects seen in cells depleted for
STING or cGAS and transfected with KSHV120. Thus, we report
that a viral protein can block STING’s interaction with TBK1 as
well as TBK1-mediated STING phosphorylation, two steps that
are critical for the response to pathogen infection.
In our cGAS-STING screen, we found that six KSHV ORFs
could significantly suppress IFN-β promoter activity and protein
levels induced by cGAS-STING activation. Although we identi-
fied multiple KSHV ORFs, only vIRF1 was further characterized
in the context of the whole virus. We found that in infected cells,
vIRF1 knockdown increased IFN-β protein levels approximately
twofold (Fig. 6B) and decreased viral gene expression approxi-
mately twofold as well (Fig. 6D). This finding suggests that, to-
gether with vIRF1, other ORFs we found in our screen also play
a role in inhibiting IFN-β even further. It is also possible that
some of the hits we found are redundant with KSHV vIRF1
function while other hits might be synergistic with vIRF1 in
inhibiting IFN induction. In summary, we demonstrate that the
cGAS-STING pathway plays important roles in primary in-
fection, as well as in viral reactivation of herpesviruses.
Methods
Cell Culture, Transfection, Plasmids, and Antibodies. HEK293T cells, Vero cells
[American Type Culture Collection (ATCC)], and EA.hy926 cells (from the
tissue culture facility at the University of North Carolina at Chapel Hill) were
grown in DMEM supplemented with FBS [10% (vol/vol)] and penicillin/
streptomycin (1%). HUVECs were purchased from the ATCC and cultured in
endothelial cell growth medium (EGM-2) supplied with growth factors
obtained from an EGM-2 Bullet kit (Lonza). More details on cell culture,
transfection, plasmids, and antibodies used in this study are provided in SI
Methods. A description of siRNA and shRNA sequences is also provided in
the SI Methods.
KSHV ORF Screen, Immunoblotting, and Coimmunoprecipitation Assays. The
KSHV ORF library has been previously described (29). Details on these assays
are provided in SI Methods.
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